Middle East And Africa Multiple Sclerosis Treatment Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 235.54 Million |
 Market Size (Forecast Year) |
USD 348.00 Million |
 CAGR |
% |
| Major Markets Players |
Middle East and Africa Multiple Sclerosis Treatment Market, By Type (Clinically isolated syndrome (CIS), Relapse-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)), Treatment (Medications, Stem Cell Therapy, Physical Therapy, Plasma Exchange, Others), Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), Diagnosis (Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
According to the National Multiple Sclerosis Society, multiple sclerosis affects about 1 million people in the United States and 2.3 million people globally. Each year, the number of people diagnosed with multiple sclerosis rises, necessitating the development of new medications that are more effective and have fewer side effects. Governments and non-government organizations in developed and developing countries are increasing their efforts to raise awareness of multiple sclerosis and giving significant funds for drug research and development.
Data Bridge Market Research analyses that the multiple sclerosis treatment market was valued at USD 235.54 million in 2021 and is expected to reach USD 348.00 million by 2029, registering a CAGR of 5.00% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Type (Clinically isolated syndrome (CIS), Relapse-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)), Treatment (Medications, Stem Cell Therapy, Physical Therapy, Plasma Exchange, Others), Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), Diagnosis (Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Hikma Pharmaceuticals PLC (UK), Merck KGaA (Germany) |
|
Market Opportunities |
|
Market Definition
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease that affects spinal cord and brain nerve cells, causing demyelination, axonal transection, and neurodegeneration. Injectable, oral, and infused medications, muscle relaxants, antidepressants, and physical therapy are some of the most widely utilized therapies. Interferon-beta and glatiramer acetate are injectable therapies that are given under the skin or into the muscle; oral medications include teriflunomide, dimethyl fumarate, and cladribine; and intravenous infusion treatments include ocrelizumab, alemtuzumab and natalizumab.
Middle East and Africa Multiple Sclerosis Treatment Market Dynamics
Drivers
- Increasing prevalence of multiple sclerosis
The rising prevalence of multiple sclerosis is a primary driver of the multiple sclerosis treatment market's growth. Relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) are the types of multiple sclerosis and their high prevalence rate will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of multiple sclerosis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multiple sclerosis treatment market. Additionally, high disposable income and increase in the development of innovative monoclonal antibodies, immunosuppressants, immunomodulators, and interferons will expand the multiple sclerosis treatment market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multiple sclerosis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the multiple sclerosis treatment market during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of multiple sclerosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the multiple sclerosis treatment market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Middle East and Africa multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Multiple sclerosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Middle East and Africa Multiple Sclerosis Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of Middle East and Africa multiple sclerosis in recent months.
Recent Development
- In August 2020, Novartis had announced the launch of Kesimpta (ofatumumab) will U.S. Food and Drug Administration (FDA) approval. It is the first and only self-administered, targeted B-cell therapy for the people suffering from relapsing multiple sclerosis. Kesimpta combines potent efficacy with an acceptable safety profile and can be self-administered at home, filling a critical gap in the treatment of replasing forms of multiple sclerosis (RMS).
Middle East and Africa Multiple Sclerosis Treatment Market Scope
The Middle East and Africa multiple sclerosis treatment market is segmented on the basis of type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Clinically isolated syndrome (CIS)
- Relapse-remitting MS (RRMS)
- Primary progressive MS (PPMS)
- Secondary progressive MS (SPMS)
Treatment
- Medications
- Injectable therapies
- Interferon-beta
- Glatiramer acetate
- Oral medications
- Dimethyl fumarate
- Teriflunomide
- Cladribine
- Intravenous infusion treatments
- Ocrelizumab
- Natalizumab
- Alemtuzumab
- Stem Cell Therapy
- Physical Therapy
- Plasma Exchange
- Others
Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
Diagnosis
- Magnetic resonance imaging (MRI)
- Simple Electrical Stimulation Tests
- Lumbar Puncture
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Middle East and Africa Multiple Sclerosis Treatment Market Regional Analysis/Insights
The Middle East and Africa multiple sclerosis treatment market is analysed and market size insights and trends are provided by country, type, treatment, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Middle East and Africa multiple sclerosis treatment market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
South Africa is expected to grow during the forecast period of 2022-2029 in Middle East and Africa region due to rising awareness about multiple sclerosis and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Multiple Sclerosis Treatment Market Share Analysis
The Middle East and Africa multiple sclerosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa multiple sclerosis treatment market.
Some of the major players operating in the Middle East and Africa multiple sclerosis treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck KGaA (Germany)
- Hikma Pharmaceuticals PLC (UK)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS
5.1.2 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITY IN MULTIPLE SCLEROSIS TREATMENT
5.1.3 RISING GOVERNMENT INITIATIVES
5.1.4 INCREASING NEED FOR BETTER MULTIPLE SCLEROSIS TREATMENT OPTIONS
5.2 RESTRAINTS
5.2.1 PATENT EXPIRY OF DRUGS
5.2.2 HIGH COST OF TREATMENT
5.3 OPPORTUNITIES
5.3.1 INCREASING AWARENESS FOR MULTIPLE SCLEROSIS TREATMENT
5.3.2 INTRODUCTION OF DISEASE-MODIFYING DRUGS
5.3.3 PRESENCE OF STRONG PIPELINE DRUGS
5.4 CHALLENGES
5.4.1 INCREASING SIDE EFFECT OF MULTIPLE SCLEROSIS MEDICATION
5.4.2 LIMITATIONS IN MULTIPLE SCLEROSIS THERAPY
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN HEALTHCARE INDUSTRY
6.1 OVERVIEW
6.2 PRICE IMPACT
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 STRATEGIC DECISIONS FOR MANUFACTURERS
6.6 CONCLUSION
7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.1 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)
7.2 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
7.3 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
7.4 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)
8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 PREVENTIVE THERAPIES
8.2.1 ORAL MEDICATION
8.2.1.1 TECFIDERA
8.2.1.2 GILENYA
8.2.1.3 AUBAGIO
8.2.1.4 MAVENCLAD
8.2.1.5 MAYZENT
8.2.1.6 VUMERITY
8.2.1.7 OTHERS
8.2.2 INJECTABLE MEDICATION
8.2.2.1 INTERFERON BETA-1A
8.2.2.1.1 AVONEX
8.2.2.1.2 REBIF
8.2.2.1.3 OTHERS
8.2.2.2 GLATIRAMER ACETATE
8.2.2.2.1 COPAXONE
8.2.2.2.2 GLATOPA
8.2.2.2.3 OTHERS
8.2.2.3 INTERFERON BETA-1B
8.2.2.3.1 BETASERON
8.2.2.3.2 EXTAVIA
8.2.2.4 PLEGRIDY/PEGINTERFERON BETA-1A
8.2.2.5 CHEMOTHERAPY DRUG
8.2.2.6 MONOCLONAL ANTIBODIES
8.2.3 INFUSED MEDICATION
8.2.3.1 TYSABRI
8.2.3.2 OCREVUS
8.2.3.3 LEMTRADA
8.2.3.4 MITOXANTRONE
8.2.3.5 NOVANTRONE
8.2.3.6 OTHERS
8.2.4 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
8.3 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS
8.3.1 CORTICOSTEROIDS
8.3.1.1 ORAL PREDNISONE
8.3.1.2 METHYLPREDNISOLONE
8.3.1.3 DEXAMETHASONE
8.3.1.4 PREDNISOLONE
8.3.1.5 BETAMETHASONE
8.3.1.6 OTHERS
8.3.2 IMMUNOSUPPRESSANTS
8.3.2.1 AZATHIOPRINE
8.3.2.2 CYCLOPHOSPHAMIDE
8.3.2.3 METHOTREXATE
8.3.2.4 MITOXANTRONE
8.3.2.5 OTHERS
8.3.3 ADRENOCORTICOTROPIC HORMONE
8.3.4 PLASMAPHERESIS
8.3.5 INTRAVENOUS IMMUNOGLOBULIN
8.3.6 OTHERS
8.4 SYMPTOMATIC THERAPIES
8.4.1.1 MUSCLE RELAXANTS
8.4.1.1.1 LIORESAL
8.4.1.1.2 ZANAFLEX
8.4.1.1.3 OTHERS
8.4.1.2 FATIGUE MEDICATIONS
8.4.1.2.1 GOCOVRI
8.4.1.2.2 OSMOLEX
8.4.1.2.3 PROVIGIL
8.4.1.2.4 RITALIN
8.4.1.2.5 OTHERS
8.4.1.3 PHYSIOTHERAPY
8.4.1.4 LAXATIVES
9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.2.1 TECFIDERA
9.2.2 GILENYA
9.2.3 AUBAGIO
9.2.4 AVONEX
9.2.5 TYSABRI
9.2.6 REBIF
9.2.7 COPAXONE
9.2.8 8 BETASERON
9.2.9 AMPYRA/FAMPYRA
9.2.10 OTHERS
9.3 GENERIC
10 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 PARENTERAL
10.3.1 INTRAVENOUS
10.3.2 SUBCUTANEOUS
10.3.3 OTHERS
11 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 HOMECARE
11.4 SPECIALTY CENTERS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.2.1 RETAIL PHARMACY
12.2.2 HOSPITAL PHARMACY
12.3 DIRECT TENDER
13 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 UAE
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
14 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT
16 COMPANY PROFILES
16.1 BIOGEN
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 NOVARTIS AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 MERCK KGAA
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 F. HOFFMANN-LA ROCHE LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 ACORDA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 1.7.4 RECENT DEVELOPMENT
16.8 ADAMAS PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AMNEAL PHARMACEUTICALS LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 BAYER AG
16.10.1 COMPANY SNAPSHOT
16.10.2 1.10.2REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 HIKMA PHARMACEUTICALS PLC
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 LANNETT
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MALLINCKRODT
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 MYLAN N.V.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 PFIZER INC.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE
TABLE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 1 MIDDLE EAST AND AFRICA RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 62 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 63 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 78 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 79 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 81 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 82 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 83 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 84 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 85 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 86 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 87 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 99 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 100 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 103 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 104 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 105 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 106 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 109 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 110 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 111 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 112 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 113 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 114 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 115 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 121 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 122 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 125 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 126 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 127 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 128 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 137 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 138 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 139 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 140 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 141 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 142 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 143 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 144 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 147 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 148 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 149 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 150 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 165 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 166 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 167 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 168 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 171 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 172 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 176 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 187 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
TABLE 188 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 191 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 192 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 193 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 10 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN 2020 & 2027
FIGURE 12 PIPELINE ANALYSIS
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET
FIGURE 14 MULTIPLE SCLEROSIS PREVALENCE
FIGURE 15 MULTIPLE SCLEROSIS PREVALENCE BY GENDER
FIGURE 16 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018
FIGURE 17 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019
FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2020-2027)
FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, 2019
FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, 2019
FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 42 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 43 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 44 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 45 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 46 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
